Glotope stands firm in its local roots while reaching out to the global market. With dual headquarters in Beijing and Chengdu, we operate state-of-the-art radiopharmaceutical R&D and production centers in Jiangsu, Guangdong, and Sichuan. Our facilities boast over 100 advanced R&D and production hot cells and qualifications for handling a variety of radionuclides, including but not limited to 225Ac, 177Lu, 212Pb, 68Ga, 18F, 64Cu, 203Pb, and 89Zr.
At Glotope, we provide adaptive and all-encompassing support to our global clientele, spanning the full spectrum of radiopharmaceutical development. From expedited PCC validation to IND submissions in China and US, from clinical trials to NDA approvals, and commercial-scale manufactering, we guarantee seamless and efficacious transitions at every phase. Our unparalleled expertise and cutting-edge facilities empower us to deliver superior solutions and prompt outcomes, driving innovation and revitalizing the radiopharmaceutical industry worldwide..